-+ 0.00%
-+ 0.00%
-+ 0.00%

Idorsia says Phase 3 PRECISION analyses show aprocitentan cuts systolic blood pressure about 15-16 mmHg in obese resistant-hypertension patients

PUBT·10/12/2026 05:00:31
Listen to the news
Idorsia says Phase 3 PRECISION analyses show aprocitentan cuts systolic blood pressure about 15-16 mmHg in obese resistant-hypertension patients
  • Idorsia reported new post hoc analyses from the Phase 3 PRECISION trial of aprocitentan in resistant hypertension patients.
  • Results were presented at the American Heart Association Hypertension Scientific Sessions 2026 on Oct. 10.
  • Analyses showed meaningful blood-pressure lowering in obesity patients and across earlier to advanced cardiovascular-kidney-metabolic stages.
  • Kidney-related markers improved or stayed stable, supporting a potential renal-protective profile alongside the blood-pressure effect.
  • Safety appeared consistent across the subgroups, reinforcing aprocitentan’s positioning as an add-on option beyond standard hypertension pathways.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120100PRIMZONEFULLFEED1001277316) on October 12, 2026, and is solely responsible for the information contained therein.